Thanks to a recent initiative at CHOP, patients newly diagnosed with B-cell and T-cell ALL, and lymphoblastic lymphoma, now go home on average 9 days after diagnosis — that's 3 weeks sooner than previous stays.

Five years after her T-cell therapy for ALL, Emily remains cancer-free. CHOP has since treated more than 170 patients in clinical trials that have seen a 93% remission rate.

The experimental, personalized cell therapy that amps up the patient's own immune system has passed a critical milestone in the path to full FDA approval.

As part of the Healthy NewsWorks student media program, student journalists interview CHOP experts for a Leading Change in Our Communities book series.

A study from Penn, CHOP finds pediatric nurses miss necessary care more often when placed in difficult work settings.

Children's Hospital of Philadelphia welcomes oculoplastic and reconstructive surgeon Karen E. Revere, MD. Dr. Revere will provide care for children and adults at both CHOP and Penn sites.

New research from CHOP and the Centers for Disease Control and Prevention finds doctors are more likely to run vision tests and implement Return-to-Learn and Play plans with electronic health tools.

A 5-year-old female presented with persistent urinary leakage. A physical examination revealed a pubis diastasis and irritation in the area of the urethra and vagina. What’s her diagnosis?

Cindy Christian, MD, Alumni Editor, writes about welcoming back Ralph DeBerardini to the Alumni Organization Pediatric Grand Rounds and shares exciting updates from two former CHOP alumni.

A DNA-cutting enzyme that regulates gene structure has a broad role in causing certain cancers. This discovery may eventually lead to more precise treatments.